Long COVID in pediatrics-epidemiology, diagnosis, and management.
Toepfner, Nicole, Brinkmann, Folke, Augustin, Silvia et al. · European journal of pediatrics · 2024 · DOI
Quick Summary
This review looked at what we know about Long COVID in children and teenagers after COVID-19 infection. Most young people recover within a few months, but some experience long-lasting symptoms like fatigue, difficulty with exercise, and anxiety that can last over a year and affect daily life. The review found that a small number of these children meet the criteria for ME/CFS, but currently there are no blood tests or scans to confirm Long COVID, making it difficult to diagnose.
Why It Matters
This review is significant for ME/CFS patients because it formally recognizes that pediatric Long COVID can progress to ME/CFS and acknowledges the diagnostic and therapeutic challenges these patients face. It highlights that current healthcare systems are inadequately equipped to manage these conditions and calls for expanded research and adapted clinical structures—directly relevant to improving care for young ME/CFS patients.
Observed Findings
Most pediatric PASC manifests after mild COVID-19 courses and remits within months, though symptoms can persist beyond 1 year in some cases.
Frequent symptoms include fatigue, exertion intolerance, and anxiety.
A subset of pediatric PASC patients present with postural tachycardia syndrome (PoTS).
A small number of cases fulfill clinical criteria for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
No validated diagnostic biomarker has been established for PASC/PCC.
Inferred Conclusions
Pediatric PASC presents with heterogeneous severity and duration, requiring individualized assessment and management.
A stepped, interdisciplinary approach is essential for appropriate clinical care of children and adolescents with PASC/PCC.
Current healthcare structures must be adapted and research expanded to meet the medical and psychosocial needs of young people with these conditions.
PASC in pediatrics represents a broader class of post-acute infection syndromes sharing similar diagnostic and therapeutic challenges.
Remaining Questions
What are the precise epidemiological differences between pediatric and adult PASC, and why do most children recover while some develop persistent ME/CFS-like illness?
What This Study Does Not Prove
This review does not establish the precise prevalence of ME/CFS in pediatric Long COVID populations, nor does it prove causative mechanisms of PASC. It also does not demonstrate the efficacy of specific treatments, as therapeutic recommendations remain based on symptom palliation and self-management rather than evidence-based interventions with proven biological targets.
What biomarkers or diagnostic criteria could reliably identify PASC/PCC and predict progression to ME/CFS in children?
Which specific therapeutic interventions (pharmaceutical or non-pharmaceutical) are most effective for pediatric PASC, and how should management be individualized based on symptom phenotype?
How should post-acute infection syndromes in children be distinguished from other conditions like deconditioning, anxiety disorders, or other organic pathologies?